EGFR and non-small cell lung carcinoma: Moreover, in a retrospective multi‐center study of 435 patients with EGFR‐mutant LA‐NSCLC, those who received definitive thoracic radiotherapy and EGFR–TKI with or without chemotherapy were associated with improved PFS (21.6 vs 12.7 months, p < 0.001) and a tendency of prolonged OS (hazard ratio = 0.65, p = 0.072) compared with those who received definitive CRT alone.34